May. 20 at 6:32 PM
$DNLI Key Recent Development: FDA Approval & Launch of AVLAYAH
On March 25, 2026, Denali received accelerated FDA approval for AVLAYAH™ (tividenofusp alfa-eknm) for the treatment of neurologic manifestations of Hunter syndrome (MPS II) in pediatric patients (presymptomatic or symptomatic, weighing ≥5 kg, before advanced neurologic impairment).
This is Denali’s first approved product. It’s notable as the first FDA-approved biologic specifically designed to cross the blood-brain barrier (BBB) and treat both central nervous system and peripheral manifestations using the company’s proprietary TransportVehicle™ (TV) platform. Approval was based on Phase 1/2 data showing reductions in heparan sulfate (a key biomarker) in cerebrospinal fluid and urine. Continued approval is contingent on the ongoing confirmatory Phase 2/3 COMPASS study. 
Launch update (as of Q1 2026 earnings, reported May 7): The U.S. commercial launch is underway and described as ahead of expectations. The first commercial patients were treated in April 2026 (within about a month of approval). Key elements like distribution, the Denali Patient Services support hub, and payer engagement with major health systems are in place. Management highlighted strong community engagement and operational execution. 
Stock Performance Snapshot (as of mid-May 2026 data)
• Price: Recently trading around
$18.10–
$18.40 (with some daily volatility; e.g., ~
$18.10 on May 19). 
• Market cap: ~
$2.9B
• 52-week range: ~
$12.58 –
$23.77
• YTD: Up ~9–10%
• 1-year: Up ~27–35%
• Recent trend: Some pullback/consolidation in the past month (down ~6–13% in recent periods) after the approval-driven moves earlier in the year.
The stock had a strong reaction to the approval news but has been consolidating as investors digest the launch ramp and broader biotech sentiment.
Financials & Pipeline
• Q1 2026 earnings (May 7): EPS of -
$0.69 slightly beat estimates. The company has a solid cash position (around
$988M) to support the launch and pipeline. 
• Pipeline highlights:
• Regained full rights to DNL593 (PTV:PGRN) for GRN-related frontotemporal dementia (FTD-GRN) in April 2026 after Takeda ended the collaboration.
• Progress on other TV-enabled programs, including first patients dosed with DNL628 (OTV:MAPT) for Alzheimer’s (tau-targeting).
• Ongoing data presentations on the TransportVehicle platform across lysosomal storage disorders.
The approval and early launch provide important platform validation for Denali’s approach to delivering large molecules (like enzymes or oligonucleotides) across the BBB.
Analyst Sentiment
Wall Street is generally bullish. Consensus is Moderate Buy / Buy, with an average 12-month price target around
$34–
$35.50 (implying substantial upside from current levels, with highs up to
$42). Recent notes highlight the AVLAYAH launch momentum and the de-risked TV platform, though some targets were trimmed slightly. 
What to Watch Next
• Launch metrics — Patient uptake, payer coverage breadth, and early revenue trends in upcoming quarters.
• COMPASS confirmatory study progress and any data readouts.
• Pipeline catalysts, especially around the regained FTD program and other TV assets.
• Overall biotech/rare disease sector sentiment.
